Eliza Hawkes

Has grant

Associate Professor

MONASH UNIVERSITY

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Eliza Hawkes is an Associate Professor at Monash University in Australia. Her research primarily focuses on lymphoma, particularly the prognostic utility of imaging techniques and the dynamics of T-cell receptor repertoires. Recent articles authored by Professor Hawkes include studies on the prediction models in Hodgkin lymphoma and the role of emerging biomarkers in lymphoma treatment strategies.

Recent Grants

Grant: Close

Optimising novel therapies to improve lymphoma patient outcomes

Open Date: 2022-10-12

Close Date:

Grant: Close

Biomarker-driven applications of immunotherapy in lymphoma

Open Date: 2018-01-01

Close Date: 2021-01-01

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (20)

Matthew Maurer

Assistant Professor of Biostatistics and Medicine

Mayo Clinic Rochester

UNITED STATES

Eliza Hawkes

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (30)

Prognostic Utility of Quantitative PET Parameters on Baseline and Interim FDG-PET Scans in Hodgkin Lymphoma

T‐Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B‐Cell Lymphoma

T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trial.

Burkitt lymphoma: click here to add to CAR-T?

Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report

Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma

The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool

PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated patients with lymphoma

Diagnosis, management and follow-up of follicular lymphoma

International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era

Correction to: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma (Leukemia, (2020), 34, 8, (2184-2197), 10.1038/s41375-020-0743-y)

Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study

Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis

Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma—Moving to a model where less can be more

Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study

Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma

The value of semiquantitative PET features and end‐of‐therapy PET in grade 3B follicular lymphoma

Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium

Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma

Diffuse large B-cell lymphoma.

Women in Lymphoma: A 4-year journey in promoting gender equity.

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

Increased STAT expression in Reed-Sternberg cells as a potential positive prognostication biomarker in Hodgkin lymphoma.

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry

Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry

Collaborators (20)

Matthew Maurer

Jamie Flerlage

Erica Wood

Chan Yoon Cheah

Tarec Christoffer El‐Galaly

David Hodgson

Andrea Gallamini

Eric Mou

Christine Smith

Sonali M. Smith

Stephen Opat

Matthew Ku

Peter Johnson

Kathryn Fleming

Katharine Lewis

colm keane

Catherine Diefenbach

Lena Specht

Ajay Major

Maher K. Gandhi

Make your next move.